Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 148 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MV\DfZRwfG:6aXOgRZN{[Xl? NIXyWos2OCEQvF2= MYO0PEBp MnS1SG1UVw>? MVXLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml MVGxNFQ6QTZ2Mx?=
OVCA 429 Mn\mSpVv[3Srb36gRZN{[Xl? MVGzNFAhdk1? M3rWbVQ5KGh? NUfWSWVKTE2VTx?= MnTpSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz MWGxNFk6QTd4Nh?=
RPMI8226 NFLBSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNFAhdk1? NGfyZm81QCCq NIPzWo5FVVOR NE\Q[3lKSzVyPUOwJI5O NGLTVVQyOTNyNkS4PS=>
Dox40 NUixR3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xNFAhdk1? NXHPcG1VPDhiaB?= MkPDSG1UVw>? M1OwOGlEPTB;NECgcm0> M3rpdVEyOzB4NEi5
MR20 NXPTV2Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TvRVExOCCwTR?= NHSyOpE1QCCq MYrEUXNQ MoOzTWM2OD1{MDDuUS=> NVHtfHl2OTF|ME[0PFk>
LR5 NFWyd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3VNVAxKG6P MYe0PEBp MY\EUXNQ MkPiTWM2OD1{MDDuUS=> NIfKWWEyOTNyNkS4PS=>
U266 NWr6PXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LyXlExOCCwTR?= M33pdlQ5KGh? NHXHSGdFVVOR NHPB[2ZKSzVyPUOgcm0> NVjtfXozOTF|ME[0PFk>
IM-9 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe3NGgyODBibl2= NX3hXZNlPDhiaB?= M3;Sc2ROW09? M1:zeWlEPTB;NjDuUS=> MkP2NVE{ODZ2OEm=
Hs Sultan MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvzNVAxKG6P MVq0PEBp MWjEUXNQ M1HJOGlEPTB;MkCgcm0> NHnZTI4yOTNyNkS4PS=>
PAM-LY2 NX7nZ|B[TnWwY4Tpc44hSXO|YYm= M2j2UVExOCCwTR?= MVOxNkBp MkfZSG1UVw>? NUTMSWtvUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> NISyfZMyOTN3MEmxNy=>
PAM 212 NWr2RopST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zQclExOCCwTR?= MX[3NkBp M3\kNGROW09? M3PpVGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NXv4dVZqOTF|NUC5NVM>
PAM-LY2 M1zOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0cVExOCCwTR?= MUS3NkBp NHHlRmxFVVOR MlvCTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MnrLNVE{PTB7MUO=
B4B8 NUHUZXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNFAhdk1? NXTUXWFLPzJiaB?= MlLxSG1UVw>? M2jYTmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NH\ndHEyOTN3MEmxNy=>
B7E3 M1O3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xNFAhdk1? NHO1TZY4OiCq NIPjcFdFVVOR M4r4RmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MXSxNVM2ODlzMx?=
UM-SCC-9 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;uVGNROTByIH7N Mlj6O|IhcA>? M1P2[mROW09? MWDJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? Mo\lNVE{PTB7MUO=
UM-SCC-11B M4HiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNFAhdk1? NEHtSnk4OiCq M4PMZWROW09? MnrVTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NGe1NXIyOTN3MEmxNy=>
H460 Mn21SpVv[3Srb36gRZN{[Xl? M{Kx[|ExKM7:TR?= NWfLRlZmOjRiaB?= NETt[HBFVVOR MVvJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NVq1eoZyOTJ2OUKxNVc>
U266 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3riOlUxOCCwZz;tcC=> NGmzOmM1QCCq NUSxWJZkTE2VTx?= MVzJcohq[mm2czDj[YxtKGe{b4f0bC=> NVfNTJRrOTJ4M{G2NVk>
ARH77 NXfyXo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG1NFAhdmdxbXy= NGnDNHA1QCCq Mn24SG1UVw>? M{PueWlvcGmkaYTzJINmdGxiZ4Lve5Rp MUexNlY{OTZzOR?=
WAD-1 NGnFZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnzO2VqPTByIH7nM41t MnXCOFghcA>? MoXWSG1UVw>? M{\xdGlvcGmkaYTzJINmdGxiZ4Lve5Rp NWS3c|BiOTJ4M{G2NVk>
U266/LR7 M4DVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XBeFUxOCCwZz;tcC=> NFX6Sm81QCCq M3KwO2ROW09? M2nxSmlvcGmkaYTzJINmdGxiZ4Lve5Rp Mn7RNVI3OzF4MUm=
U266/dox4 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnmfJpMPTByIH7nM41t MlnsOFghcA>? NXvEdnJJTE2VTx?= NFHWbYlKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NWPIWnQ{OTJ4M{G2NVk>
RPMI8226/LR5 M4\FR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT4fGtPPTByIH7nM41t NHjvR2M1QCCq NHu0R4pFVVOR M2HFNmlvcGmkaYTzJINmdGxiZ4Lve5Rp M2PzUlEzPjNzNkG5
H460 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXJNVAh|ryP Mn\HO|IhcA>? NIDUWoVFVVOR M{P5UWlEPTB;MUCwJI5O Mli2NVI3OzF4MkC=
H358 NEO1V21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxNEDPxE1? MoTEO|IhcA>? NXnJUIk6TE2VTx?= NEezNXlKSzVyPUewJI5O NFSwe|QyOjZ|MU[yNC=>
H322 M4fB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jpNFExKM7:TR?= NHvsSmc4OiCq MV\EUXNQ MXnJR|UxRTZ{MDDuUS=> M2rW[FEzPjNzNkKw
H460 Mn:0SpVv[3Srb36gRZN{[Xl? MVyxNFAhdk1? NVf1XW0xOjRiaB?= NX3HVocxTE2VTx?= M2Lpc2lv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? Ml7ONVI3OzF4MkC=
LNCap-Pro5 Mn3JSpVv[3Srb36gRZN{[Xl? M13tS|Eh|ryP M3rF[FQhcA>? MVPEUXNQ NFrVWlhUfGGkaXzpfoV{KHB3Mx?= Mn;ENVQ3OTJ3M{K=
T29 NGLJZnFCeG:ydH;zbZMhSXO|YYm= NF7TPFM2OCCwTR?= NYrMVWdVPDhiaDC= NXW3cotmTE2VTx?= NFzsfI5KdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlH1NVY4PzhzN{m=
T29Kt1 MX;BdI9xfG:|aYOgRZN{[Xl? MWK1NEBvVQ>? NWfwS2hLPDhiaDC= NVXocXRITE2VTx?= NFjWXIJKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3TPUFE3Pzd6MUe5
HCT116 NXP0ZYZFSXCxcITvd4l{KEG|c3H5 NXfsXlg6PTBibl2= NYDKSHl5PDhiaDC= NHHSWpdFVVOR NHnV[5FKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYn0OpdpOTZ5N{ixO|k>
HKe-3 NIPYcHpCeG:ydH;zbZMhSXO|YYm= NX3JPY1LPTBibl2= NVHD[GlDPDhiaDC= MYfEUXNQ NYXrN|hVUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MWWxOlc4QDF5OR?=
NB-1691 NFmxXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\iUFEh|ryP M3faNFczKGh? M3XNTGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= M2X1[lE4Pjh7Nki0
CHLA-255 NHX0NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rPW|Eh|ryP NF35S204OiCq MlfGTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn MWCxO|Y5QTZ6NB?=
SK-N-AS M2W4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjNOoNmOSEQvF2= MVW3NkBp M4TL[mlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= NXT6W4ZUOTd4OEm2PFQ>
NB-1691 M{PoNWZ2dmO2aX;uJGF{e2G7 NH61SlgyOCCwTR?= MYmyOEBp NXHsRY05W2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NYHORXNTOTd4OEm2PFQ>
CHLA-255 MnHHSpVv[3Srb36gRZN{[Xl? MV:xNEBvVQ>? MoDZNlQhcA>? MV;Nc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NWW3W5VrOTd4OEm2PFQ>
RPMI 8226 NYj4UpBNTnWwY4Tpc44hSXO|YYm= NF;VV3AzOCCwTR?= M3PYZVghcA>? NFfZVFlUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M{S0XVE6PDN4MEWw
MM.1S MXTGeY5kfGmxbjDBd5NigQ>? NVHWZZZtOjBibl2= Mn7zPEBp Mn[4V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M3SwXFE6PDN4MEWw
U266 NU\oXndFTnWwY4Tpc44hSXO|YYm= MXWyNEBvVQ>? NU\MdHFQQCCq NInCWpFUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NXjCe4JrOTl2M{[wOVA>
OPM1 M2C0NWZ2dmO2aX;uJGF{e2G7 MUmyNEBvVQ>? NYfXTGNiQCCq MUHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MWKxPVQ{PjB3MB?=
INA6 MW\GeY5kfGmxbjDBd5NigQ>? M{H0dVIxKG6P M4nTPVghcA>? MnjEV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NH3HUnIyQTR|NkC1NC=>
OPM2 NWHpXVhETnWwY4Tpc44hSXO|YYm= NFG1UI0zOCCwTR?= M33mXlghcA>? NWrRVZF7W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MWSxPVQ{PjB3MB?=
RPMI 8226 M2PoWmZ2dmO2aX;uJGF{e2G7 MVOyNEBvVQ>? NXj6cmY5QCCq MmXBTY5lfWOnczDEUmEhe3mwdHjld4l{ MoHnNVk1OzZyNUC=
BaF/3 NX:0XFRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS4S5pwOTByIH7N MWm0PEBp MVLJR|UxRTZwMjDuUS=> NYDXSXFmOjB|MEW2PVI>
BaF/3-p210 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nDcFExOCCwTR?= M3O1bVQ5KGh? M2rwR2lEPTB;ND63JI5O NYnrW4IyOjB|MEW2PVI>
TCC-S MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNFAhdk1? M{XSUFQ5KGh? NWniVWM1UUN3ME2yMlghdk1? NX;1WVFsOjB|MEW2PVI>
BaF/3 Mn3OSpVv[3Srb36gRZN{[Xl? MV62JI5O NHrOfmE1QCCq MYTJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= M37pT|IxOzB3Nkmy
BaF/3-p210 NITTOW9HfW6ldHnvckBCe3OjeR?= M1fsVlYhdk1? MXm0PEBp NFS0NGFKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 NGLBWo0zODNyNU[5Ni=>
BaF/3-p210 M1\tSmZ2dmO2aX;uJGF{e2G7 MlTtOkBvVQ>? NX;0VFB7OjRiaB?= MmfXVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? M2HiZ|IxOzB3Nkmy
Raji NV70cmZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOwV3gyKM7:TR?= NI\reVczPCCq MmjkVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NUL0RnhHOjFzN{C5PFg>
LCL-1 M2rGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF36UYoyKM7:TR?= MYSyOEBp MkDnVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NVjtPWJWOjFzN{C5PFg>
LCL-2 NHm3PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y3[VEh|ryP M3u1ZVI1KGh? M1vrV3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M1LOTVIyOTdyOUi4
BJAB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP1NUDPxE1? MlO2NlQhcA>? M1v1dHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MmjqNlEyPzB7OEi=
SNT-13 NV3xToRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;EN|Eh|ryP NX;kcFRyOjRiaB?= NGPzOnNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M4HBcFIyOTdyOUi4
SNT-16 NWD2ZnZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrodpoyKM7:TR?= MXyyOEBp MkC5VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M4W0V|IyOTdyOUi4
Jurkat MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxJO69VQ>? MlzCNlQhcA>? NH3EUYhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MUOyNVE4ODl6OB?=
KAI-3 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxJO69VQ>? MUKyOEBp NVjwOIluWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MWGyNVE4ODl6OB?=
SNK-6 NHf1R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PaSlEh|ryP Mnq4NlQhcA>? NE\6T3FT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= Mn\ENlEyPzB7OEi=
KHYG-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HZd|Eh|ryP MnjmNlQhcA>? MmTHVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M2HV[|IyOTdyOUi4
SNT-16 NHPKZ2dCeG:ydH;zbZMhSXO|YYm= NYfwOmM6OSEQvF2= NWq0Soo{PiCq NU\LTFE2UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3j4VVIyOTdyOUi4
Jurkat M{LhdmFxd3C2b4Ppd{BCe3OjeR?= NX7R[nEzOSEQvF2= MUi2JIg> M1XuUmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUG4dINlOjFzN{C5PFg>
KAI-3 MlHURZBweHSxc3nzJGF{e2G7 MkjwNUDPxE1? NFPTfnc3KGh? NF\XVJZKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{jGWFIyOTdyOUi4
KHYG-1 MVnBdI9xfG:|aYOgRZN{[Xl? MYmxJO69VQ>? MVq2JIg> M3rnTWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmriNlEyPzB7OEi=
SNT-13 M4XQVmFvfGm4aYLhcEBCe3OjeR?= NWXqdYU3OSEQvF2= NU\Hcol[OjRiaB?= MXTJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MUKyNVE4ODl6OB?=
SNT-16 MVjBcpRqfmm{YXygRZN{[Xl? MV[xJO69VQ>? MX:yOEBp M2rvS2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MWmyNVE4ODl6OB?=
KAI-3 NW\mRmJuSW62aY\pdoFtKEG|c3H5 NGjmWm8yKM7:TR?= NFvmWmszPCCq NH7oOWxKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? M4K3SVIyOTdyOUi4
SNK-6 M{nSWWFvfGm4aYLhcEBCe3OjeR?= NF3lcZEyKM7:TR?= M2HNWlI1KGh? MmXQTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NVLuPWRkOjFzN{C5PFg>
RAW 264.7 NHriSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNFAhdk1? MmTHOFghcA>? NUjsVIpDWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M{\SZlIzPDJ5MUW0
A375 M4\5XmFxd3C2b4Ppd{BCe3OjeR?= NXvVb2tEOTBibl2= NEe5SlUzPCCq MnuyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NISwV3AzOzB5OUC4Ny=>
BLM NHLU[4FCeG:ydH;zbZMhSXO|YYm= MUCxNEBvVQ>? MVmyOEBp NVm0R|JSUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFu0co8zOzB5OUC4Ny=>
A375 MXnBeZRweGijZ4mgRZN{[Xl? M1\zRVExKG6P NYjxT|dtOTJiaB?= NUjaU2hVUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NVPIV2xvOjNyN{mwPFM>
BLM MoTkRZV1d3CqYXf5JGF{e2G7 Mn74NVAhdk1? M2e0TlEzKGh? Mm\6TY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NXPEZlNFOjNyN{mwPFM>
H1299 M1PNWGFxd3C2b4Ppd{BCe3OjeR?= MmDjPFAhdk1? MWWyOEBp NILxW4RFVVOR NYTYRZQ4W2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= NYjLNW56OjV|MkO2PVM>
Hut-78 M{K5WGZ2dmO2aX;uJGF{e2G7 M3nIcVExOCCwTR?= NIDN[|IzPCCq NUPT[mlLTE2VTx?= M3jpXmRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= NXPFWIhPOjV4OEGzN|U>
H9 NX;IeItmTnWwY4Tpc44hSXO|YYm= MYexNFAhdk1? M1rXSlI1KGh? MlX5SG1UVw>? NG\qNXRFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36= MYCyOVY5OTN|NR?=
HH NYnueoM2TnWwY4Tpc44hSXO|YYm= MWmxNFAhdk1? NXnqOXV{OjRiaB?= NXvGe4dKTE2VTx?= MWjkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? NWHkdndwOjV4OEGzN|U>
Hut-78 MkLJUYloemG2aX;uJGF{e2G7 MoHNNVAxKG6P M4L3XlI1KGh? NYD6c5E4TE2VTx?= NIXTbldT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl Ml7LNlU3QDF|M{W=
HH NGLwRopOcWe{YYTpc44hSXO|YYm= NEXoRnEyODBibl2= NWGzUII2OjRiaB?= NIXWO5RFVVOR MlHyVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= NYTYOGJMOjV4OEGzN|U>
U937 M2fRT2Z2dmO2aX;uJGF{e2G7 NF7ZUmIyODBibl2= NWDTW2g4PiCq NX7w[nBbUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?= NWnOSpQxOjV5OUG0O|c>
human PBMC M{X1RWZ2dmO2aX;uJGF{e2G7 NUOzV4VLOTByIH7N NE\BdFEzPCCq MVTJcoR2[2W|IFnMMVghemWuZXHz[S=> MoTJNlU4QTF2N{e=
ES6 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqzWVZvUUN3ME2wMlAxOjFibl2= NUfjOIdyW0GQR1XS
SK-UT-1 NF;MNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\JOppKSzVyPUCuNVY{KG6P M1GzWHNCVkeHUh?=
SH-4 NVzBPGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUezJI5O MlTYV2FPT0WU
TE-9 NGPhVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD1yLkG4NkBvVQ>? M{fudHNCVkeHUh?=
A253 M4jw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHjZ|BoUUN3ME2wMlIxQCCwTR?= MlnVV2FPT0WU
no-10 M{XyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\oTWM2OD1yLkKxJI5O MnO1V2FPT0WU
MMAC-SF MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMkG2JI5O Mlv1V2FPT0WU
A101D Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\sO4xKSzVyPUCuNlI2KG6P NV3vOYs2W0GQR1XS
NTERA-S-cl-D1 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQTWM2OD1yLkK0N{BvVQ>? NGjRTINUSU6JRWK=
8-MG-BA NWjxT3RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMkWgcm0> NYrCZmxvW0GQR1XS
KNS-42 NF\xcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMkW4JI5O NGfUPGlUSU6JRWK=
LXF-289 M1PnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMk[5JI5O NFG3Z3hUSU6JRWK=
OVCAR-4 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[4V2lEPTB;MD6yPFkhdk1? MXzTRW5ITVJ?
LOUCY NHn4eIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMkmzJI5O M3nNfnNCVkeHUh?=
BB65-RCC NVK2Tll[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XFUGlEPTB;MD6zNFQhdk1? NV:3UoczW0GQR1XS
D-542MG NWfUbnVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz6VohKSzVyPUCuN|I6KG6P M1TVNHNCVkeHUh?=
ONS-76 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES1blZKSzVyPUCuN|Mhdk1? MoTyV2FPT0WU
BB30-HNC NIDGfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorETWM2OD1yLkOzOUBvVQ>? M3v0XHNCVkeHUh?=
KS-1 M2\1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDETWM2OD1yLkO0JI5O MWnTRW5ITVJ?
A388 NFHpZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3oTWM2OD1yLkO1OkBvVQ>? M2nz[3NCVkeHUh?=
ES8 M2qydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNDDuUS=> M2q4NXNCVkeHUh?=
MZ2-MEL NVy3XGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrtdVdKSzVyPUCuOFA4KG6P NVG3WI86W0GQR1XS
HCC2998 NXPJVYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorKTWM2OD1yLkSxNkBvVQ>? MmS0V2FPT0WU
D-247MG NH3r[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED1d45KSzVyPUCuOFE{KG6P NYLSSWM6W0GQR1XS
ACN NXHOfGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n4PGlEPTB;MD60NVchdk1? NHm2doxUSU6JRWK=
LB2518-MEL M1WxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nzZWlEPTB;MD60NlUhdk1? MoG4V2FPT0WU
ES1 NGDhT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GSlhKSzVyPUCuOFMhdk1? NV\JZ2h{W0GQR1XS
HCE-T NF[yOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn1XYtKSzVyPUCuOFM6KG6P NWDaXmVPW0GQR1XS
OS-RC-2 NWfZWGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPGfXp{UUN3ME2wMlQ1KG6P MnX4V2FPT0WU
MFH-ino NVK2WYFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD1yLkS0N{BvVQ>? MXfTRW5ITVJ?
OCUB-M NFLkPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rHNmlEPTB;MD60OFchdk1? NXPoOJhpW0GQR1XS
CP66-MEL M3HkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT3[odMUUN3ME2wMlQ4OyCwTR?= MknSV2FPT0WU
LB771-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXyxU5pjUUN3ME2wMlQ4PCCwTR?= M{LsWXNCVkeHUh?=
DSH1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXyU3lKSzVyPUCuOFghdk1? MYjTRW5ITVJ?
HUTU-80 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonMTWM2OD1yLkWzN{BvVQ>? MlTtV2FPT0WU
CESS M3S0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNUO4JI5O NVT4Z4k6W0GQR1XS
NCI-H747 M4nJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr0TWM2OD1yLkWzPUBvVQ>? NEPMUZpUSU6JRWK=
HT-144 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETINJpKSzVyPUCuOVc3KG6P NYHUTZAzW0GQR1XS
COLO-829 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPjZoZKSzVyPUCuOlE1KG6P MlnuV2FPT0WU
A4-Fuk M{XW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DqWmlEPTB;MD62NlMhdk1? NYP0eWF[W0GQR1XS
GI-ME-N Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwNkO0JI5O M3zGfnNCVkeHUh?=
LB831-BLC NHP1SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv0VmdKSzVyPUCuOlQyKG6P MnS1V2FPT0WU
HOP-62 NWjWT5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNkS3JI5O NYn6SIZOW0GQR1XS
BB49-HNC M{XrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG1UGxpUUN3ME2wMlY2OiCwTR?= MkSyV2FPT0WU
D-336MG M2TWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH3c5lvUUN3ME2wMlY2PyCwTR?= NGHIRmRUSU6JRWK=
TK10 NVn3UFdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNke5JI5O NXPtbo5MW0GQR1XS
Ramos-2G6-4C10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvwTWM2OD1yLk[5N{BvVQ>? MWPTRW5ITVJ?
LB373-MEL-D MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzMWIlCUUN3ME2wMlchdk1? NVnJfGdqW0GQR1XS
SF126 NXLwdVRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L6WGlEPTB;MD63NFEhdk1? NH\POW9USU6JRWK=
UACC-257 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwN{Ggcm0> NXqycHVnW0GQR1XS
KINGS-1 NVXJc45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnM[YhyUUN3ME2wMlczOiCwTR?= M4TLTnNCVkeHUh?=
LS-513 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwN{O5JI5O NFjUc3VUSU6JRWK=
GI-1 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorlTWM2OD1yLke2OEBvVQ>? M3XvNHNCVkeHUh?=
ES7 NXLMWWFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvLcW5KSzVyPUCuO|Y3KG6P NYLGWmVkW0GQR1XS
LB2241-RCC MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjSUpJKSzVyPUCuPFA1KG6P Mk\KV2FPT0WU
D-263MG M2TUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\4TWM2OD1yLkiwO{BvVQ>? NYK5SHBuW0GQR1XS
SW684 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17nWmlEPTB;MD64NlEhdk1? NHvFWolUSU6JRWK=
ML-2 M4K5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGwbGMxUUN3ME2wMlgzOSCwTR?= M4fyeXNCVkeHUh?=
SK-LMS-1 NV3R[YdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP5RoFKSzVyPUCuPFU1KG6P M13tUHNCVkeHUh?=
TE-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwOE[1JI5O NHWx[pFUSU6JRWK=
QIMR-WIL NFXobGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DJdmlEPTB;MD64PFkhdk1? MVLTRW5ITVJ?
NCI-H1355 M2\udWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljrTWM2OD1yLki5OUBvVQ>? MorzV2FPT0WU
SNB75 NE\4O3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DkU2lEPTB;MD65NVIhdk1? NFz6d25USU6JRWK=
RXF393 NXPqPXRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnMNGtKSzVyPUCuPVE1KG6P MWnTRW5ITVJ?
IST-MEL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjqVotHUUN3ME2wMlkyPyCwTR?= NUPWeYZOW0GQR1XS
SF268 M3jKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSzTWM2OD1yLkmyN{BvVQ>? NV74d5E4W0GQR1XS
KALS-1 NG\kVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Prc2lEPTB;MD65NlUhdk1? NYKx[ZBkW0GQR1XS
HC-1 NHPib3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\qbmlEPTB;MD65O|Uhdk1? NHXQSmFUSU6JRWK=
SW872 NEXqd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwOUm2JI5O NUHUWFVYW0GQR1XS
PSN1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMEGgcm0> NVPwTlYzW0GQR1XS
TE-1 M1ywUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPyeVdKSzVyPUGuNFMhdk1? NYP1UJhSW0GQR1XS
TE-10 M4\D[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMEOgcm0> MnXYV2FPT0WU
RKO NX;NVG52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwME[gcm0> NYrDOJFRW0GQR1XS
LC-2-ad NUfmelNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwMEigcm0> NIPJVGlUSU6JRWK=
SK-MM-2 NF;hUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nCSGlEPTB;MT6wPUBvVQ>? M4TYT3NCVkeHUh?=
VA-ES-BJ M1uxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqTWM2OD1zLkC5JI5O MnzWV2FPT0WU
MZ7-mel MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrYfVdKSzVyPUGuNFkhdk1? NHLpc3pUSU6JRWK=
D-392MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnXeJlqUUN3ME2xMlEhdk1? MmDpV2FPT0WU
CCRF-CEM M2TuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXFdJI3UUN3ME2xMlE{KG6P NEm2XnJUSU6JRWK=
EM-2 NEHXNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjVdFdoUUN3ME2xMlE3KG6P M4H4dXNCVkeHUh?=
HAL-01 NX70TW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HFRmlEPTB;MT6xPEBvVQ>? M{mySHNCVkeHUh?=
TE-8 NV;2V2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXHVWJKSzVyPUGuNVkhdk1? MWTTRW5ITVJ?
NCI-H1882 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDOS|BoUUN3ME2xMlIhdk1? MUHTRW5ITVJ?
Daudi NXqwcngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwMkKgcm0> NFvLT3FUSU6JRWK=
BL-41 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV61eJVzUUN3ME2xMlI2KG6P MVHTRW5ITVJ?
SR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwMkWgcm0> NVnyOVFlW0GQR1XS
KM12 M{nRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr2TWM2OD1zLkK3JI5O MnzMV2FPT0WU
K5 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj0UGZHUUN3ME2xMlI5KG6P NITOXnRUSU6JRWK=
A3-KAW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH23eZpKSzVyPUGuNlghdk1? MWnTRW5ITVJ?
CMK NGHPbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknyTWM2OD1zLkK5JI5O MlLKV2FPT0WU
Calu-6 M4TTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT1WXJZUUN3ME2xMlI6KG6P M1zkXnNCVkeHUh?=
IST-SL2 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P6dGlEPTB;MT6zNUBvVQ>? NFvmZXFUSU6JRWK=
OPM-2 M1HvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGyeWVKSzVyPUGuN|Mhdk1? M2fZNnNCVkeHUh?=
DU-4475 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjR[ndKSzVyPUGuN|Yhdk1? Mn\rV2FPT0WU
ECC12 NV;tXVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfNW|hMUUN3ME2xMlM4KG6P MnT4V2FPT0WU
L-540 NF3mbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7ZW5l2UUN3ME2xMlM4KG6P NXjuVYtKW0GQR1XS
CAS-1 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK1WGY4UUN3ME2xMlM4KG6P NWP0cYxvW0GQR1XS
PF-382 M4myO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjPPZdKSzVyPUGuOFchdk1? NGTER4dUSU6JRWK=
LS-411N NYHvbppQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ThVmlEPTB;MT61N{BvVQ>? NHfHSoZUSU6JRWK=
NCI-H69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XndmlEPTB;MT61OEBvVQ>? NXTvcJo1W0GQR1XS
NB12 M2[1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHUXHBrUUN3ME2xMlU3KG6P M3vrNXNCVkeHUh?=
HEL NYHYOYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ryOGlEPTB;MT62NUBvVQ>? MXvTRW5ITVJ?
GCIY M2Sxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r1eGlEPTB;MT62NkBvVQ>? NFjNN5hUSU6JRWK=
EHEB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHyVmFKSzVyPUGuOlchdk1? M1;WfHNCVkeHUh?=
TGBC1TKB M3TXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vCUGlEPTB;MT63NUBvVQ>? MXPTRW5ITVJ?
KURAMOCHI NEHFcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFNGlEPTB;MT63NkBvVQ>? NXXado1SW0GQR1XS
U-266 NV;kdWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLPTWM2OD1zLke2JI5O NH;5NXNUSU6JRWK=
LC4-1 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjz[WRPUUN3ME2xMlc6KG6P M333[nNCVkeHUh?=
NCI-H2126 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL2TWM2OD1zLkigcm0> MVjTRW5ITVJ?
NCI-H1092 NV31TIN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rhcWlEPTB;MT64JI5O M37oNHNCVkeHUh?=
GB-1 NX;ZcI0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjwVnFOUUN3ME2xMlgyKG6P NUPyV2VjW0GQR1XS
MV-4-11 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwOEKgcm0> NH;6UohUSU6JRWK=
Becker NESyTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3UfIpKSzVyPUGuPFMhdk1? MWHTRW5ITVJ?
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnETWM2OD1zLki5JI5O MX\TRW5ITVJ?
BE-13 NXG3SVFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zNNGlEPTB;MT65N{BvVQ>? NI\EWWxUSU6JRWK=
697 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PUWGlEPTB;MT65PUBvVQ>? NFLPZ5ZUSU6JRWK=
NKM-1 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\LcnhKSzVyPUKgcm0> MWjTRW5ITVJ?
NB13 NEDEVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJibl2= NUTvO21sW0GQR1XS
LS-123 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPCTWM2OD1{LkCyJI5O Mn2wV2FPT0WU
NB17 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\2TWM2OD1{LkC0JI5O NFzxWWRUSU6JRWK=
LAN-6 M4XzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwMEWgcm0> MnnSV2FPT0WU
EW-24 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfXU5pVUUN3ME2yMlA5KG6P NYq4enpMW0GQR1XS
NOS-1 M{CwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTW3JKSzVyPUKuNVEhdk1? MYrTRW5ITVJ?
BL-70 NXLVTpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki0TWM2OD1{LkGyJI5O M2rRN3NCVkeHUh?=
GT3TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPseFNEUUN3ME2yMlEzKG6P MWPTRW5ITVJ?
HH NG\afW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7re5A2UUN3ME2yMlE{KG6P NEKybIpUSU6JRWK=
KE-37 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHx[4pKSzVyPUKuNVMhdk1? NXLXTWhOW0GQR1XS
MOLT-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwMUOgcm0> NE\mSm5USU6JRWK=
EKVX M2fKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH34fINKSzVyPUKuNVQhdk1? NFXIc|hUSU6JRWK=
KGN NEn3eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOwNm51UUN3ME2yMlE2KG6P MUHTRW5ITVJ?
ES4 M{fIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJwMU[gcm0> MYTTRW5ITVJ?
SJSA-1 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPDb4ZKSzVyPUKuNlEhdk1? NWrG[oRFW0GQR1XS
KMOE-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvRUGFmUUN3ME2yMlI{KG6P NIXheJVUSU6JRWK=
NB5 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[4UJZXUUN3ME2yMlI4KG6P Ml\wV2FPT0WU
BC-1 M4fFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rL[2lEPTB;Mj6zNUBvVQ>? NH\CbGNUSU6JRWK=
NB10 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn2TWM2OD1{LkOyJI5O NGnJRpVUSU6JRWK=
RPMI-8226 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXBNJI5UUN3ME2yMlM2KG6P MVnTRW5ITVJ?
SCC-3 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPwTWM2OD1{LkO3JI5O NE\yfmhUSU6JRWK=
ARH-77 NGHFb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PuPWlEPTB;Mj6zPEBvVQ>? NXfCSZBvW0GQR1XS
NCI-H748 NEG5N|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjLOWVGUUN3ME2yMlM6KG6P M3XNcXNCVkeHUh?=
KU812 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD4OVFrUUN3ME2yMlQzKG6P MXTTRW5ITVJ?
NCI-H64 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwNESgcm0> NXnmS4oxW0GQR1XS
NB69 NFK3VXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGzcoVKSzVyPUKuOFYhdk1? M3XWZnNCVkeHUh?=
KNS-81-FD MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXiTWM2OD1{LkS4JI5O M4\1THNCVkeHUh?=
LB1047-RCC M4LnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHxe4hqUUN3ME2yMlU4KG6P MV\TRW5ITVJ?
EB-3 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\JTWM2OD1{Lk[2JI5O MkHhV2FPT0WU
Mo-T NHLQW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfOTWM2OD1{Lke0JI5O NVrpdYs{W0GQR1XS
EW-16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLBe2Y4UUN3ME2yMlc2KG6P MmrBV2FPT0WU
CTV-1 M{\ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGyWYNKSzVyPUKuPEBvVQ>? NED6fIlUSU6JRWK=
ETK-1 M1HIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwOESgcm0> MnezV2FPT0WU
C2BBe1 M{XsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwOEmgcm0> MXfTRW5ITVJ?
MOLT-16 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3Lc41KSzVyPUKuPFkhdk1? MkH0V2FPT0WU
SW954 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrBTWM2OD1{Lkmgcm0> MmDWV2FPT0WU
HT MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH2ZXU2UUN3ME2zMlAzKG6P MkLHV2FPT0WU
KARPAS-299 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXHR|NKSzVyPUOuNFYhdk1? NUTJVmpoW0GQR1XS
MONO-MAC-6 M1;Nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwMTDuUS=> M1nxPHNCVkeHUh?=
CGTH-W-1 M1TxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkflTWM2OD1|LkGgcm0> NHH2bIJUSU6JRWK=
SK-PN-DW MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7MNo1KSzVyPUOuNVQhdk1? M3v6UHNCVkeHUh?=
CW-2 NUOyNZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHrNFUxUUN3ME2zMlIyKG6P NUThO|FzW0GQR1XS
SK-N-DZ NVn2THhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7K[5E6UUN3ME2zMlI3KG6P NIfjeGlUSU6JRWK=
NEC8 NFTZcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfaWXNKSzVyPUOuN|Uhdk1? NYPodHBTW0GQR1XS
LB996-RCC M3vHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PxTGlEPTB;Mz60JI5O NGXnZXlUSU6JRWK=
DB M2K1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwNEGgcm0> MkPqV2FPT0WU
TE-15 NXe3b5JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED3b2NKSzVyPUOuOFMhdk1? MkLQV2FPT0WU
COR-L88 NHy0WYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\KTWM2OD1|LkS3JI5O MmHUV2FPT0WU
LAMA-84 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTYeplKSzVyPUOuOFkhdk1? NGKxS|lUSU6JRWK=
MEG-01 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNwNEmgcm0> NVvtZXg1W0GQR1XS
LOXIMVI M3H0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r6V2lEPTB;Mz61JI5O MUTTRW5ITVJ?
RPMI-8402 M2G2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL2TXhKSzVyPUOuOUBvVQ>? M3foZnNCVkeHUh?=
KARPAS-45 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPJNnVGUUN3ME2zMlU1KG6P MnjhV2FPT0WU
HCC1187 NXTJWow{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3nNGZKSzVyPUOuOVQhdk1? MnzuV2FPT0WU
MZ1-PC NULjfY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwNUSgcm0> M4nCZ3NCVkeHUh?=
no-11 MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj4TWM2OD1|LkW1JI5O MlrRV2FPT0WU
EVSA-T M3fldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwNjDuUS=> MUjTRW5ITVJ?
DJM-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHlTWM2OD1|Lk[zJI5O MnK2V2FPT0WU
COLO-684 M4XJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LjU2lEPTB;Mz62OkBvVQ>? Mlm3V2FPT0WU
NMC-G1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\4TWM2OD1|Lk[4JI5O M3OwXXNCVkeHUh?=
LC-1F NVzNWVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH0VYdKSzVyPUOuO|Qhdk1? NIGwVVFUSU6JRWK=
RL95-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP6TWM2OD1|Lke5JI5O Mn7mV2FPT0WU
COLO-320-HSR NVvMc3d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDCTHRyUUN3ME2zMlkzKG6P MWDTRW5ITVJ?
RCC10RGB MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrtTWM2OD1|LkmzJI5O NIfBOnhUSU6JRWK=
HD-MY-Z NWHrZodRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fGUmlEPTB;Mz65N{BvVQ>? MoDFV2FPT0WU
NCI-H2141 M1\Od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LnZWlEPTB;ND6wOUBvVQ>? MlTaV2FPT0WU
K-562 NH3lb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRwMUKgcm0> MV3TRW5ITVJ?
NCI-H1648 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnGbpVDUUN3ME20MlE{KG6P MonBV2FPT0WU
OMC-1 NYTTd2JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwbHdKSzVyPUSuNVghdk1? NEjiN2pUSU6JRWK=
LB647-SCLC NXO2U2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO1bmI3UUN3ME20MlIzKG6P M4nJOXNCVkeHUh?=
TE-12 M4nhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofJTWM2OD12LkK1JI5O Mn\hV2FPT0WU
NOMO-1 NX;4WmNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC5SHhIUUN3ME20MlM{KG6P NWDldHUzW0GQR1XS
Raji NGnxNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHIdpVKSzVyPUSuOFYhdk1? NInQeWlUSU6JRWK=
NALM-6 NWraRo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPUTWM2OD12LkS5JI5O NFvHfIhUSU6JRWK=
HL-60 NEX4[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3WOIdKSzVyPUSuOlchdk1? MlzzV2FPT0WU
IST-SL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnCTWM2OD12Lk[4JI5O NVLyTIp7W0GQR1XS
MHH-PREB-1 NX;JSXRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLkZ5luUUN3ME20Mlg3KG6P M2XyUXNCVkeHUh?=
MHH-NB-11 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2exbGlEPTB;ND65NUBvVQ>? NEj5XYVUSU6JRWK=
JiyoyeP-2003 NHO4RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\O[2lEPTB;NTDuUS=> NELpToNUSU6JRWK=
SBC-1 NF;VXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HmdmlEPTB;NT6wNUBvVQ>? MXzTRW5ITVJ?
CHP-126 NYfsbGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVwME[gcm0> NV\jeVA2W0GQR1XS
LU-139 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojJTWM2OD13LkGzJI5O NYjBO4NbW0GQR1XS
NCI-SNU-5 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYTWM2OD13LkG3JI5O NFnSO5dUSU6JRWK=
SW962 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOxTlNHUUN3ME21MlIyKG6P NIm2bo1USU6JRWK=
EW-1 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzUTWM2OD13LkOxJI5O MXfTRW5ITVJ?
NCI-H1417 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXIR2xzUUN3ME21MlUyKG6P M3XSOnNCVkeHUh?=
LU-65 NXfsO|lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTVwOESgcm0> M4H6W3NCVkeHUh?=
D-502MG NX\XW2ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TZSGlEPTB;Nj6zO{BvVQ>? MnTNV2FPT0WU
BC-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLCdGNzUUN3ME22MlYyKG6P NV75PFdjW0GQR1XS
GDM-1 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[4TWM2OD14Lke3JI5O M{j4bnNCVkeHUh?=
NCI-H2196 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlTWM2OD14Lkigcm0> NI\HN5dUSU6JRWK=
NB1 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPhenhYUUN3ME22Mlg5KG6P MU\TRW5ITVJ?
NCI-H345 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP5UZJiUUN3ME23MlIhdk1? NX\SN|R[W0GQR1XS
SU-DHL-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNR5hKSzVyPUeuNlQhdk1? MUnTRW5ITVJ?
JVM-2 NVHqWXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rwSWlEPTB;Nz6yPEBvVQ>? M2L5dXNCVkeHUh?=
LU-134-A NWn3bVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTdwM{mgcm0> NYPQNopTW0GQR1XS
NCI-H1694 M{D0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPte4VKSzVyPUeuOVghdk1? NX7IeI9vW0GQR1XS
NCI-SNU-16 NFjGUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfNTWM2OD15Lk[1JI5O MlTHV2FPT0WU
L-363 NEW2[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfNTWM2OD15Lkegcm0> MWHTRW5ITVJ?
KG-1 M4T0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfnTWM2OD15Lkm0JI5O M1LkV3NCVkeHUh?=
MN-60 NG\Ifm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRThwMUSgcm0> NX20c4xGW0GQR1XS
NB6 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jHRWlEPTB;OD60PEBvVQ>? MW\TRW5ITVJ?
MLMA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[1bGlEPTB;OD64OUBvVQ>? MnfLV2FPT0WU
ATN-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvBT|NLUUN3ME24Mlg6KG6P MmS2V2FPT0WU
SK-NEP-1 M2fqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK2TWM2OD17LkCxJI5O MlHXV2FPT0WU
DMS-114 NEf5[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LXcGlEPTB;OT62NkBvVQ>? MkjOV2FPT0WU
CTB-1 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;YXGlEPTB;OT62O{BvVQ>? NV70SFhUW0GQR1XS
NCI-H2081 NIrnW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfoNG9KSzVyPUGwMlA6KG6P MXPTRW5ITVJ?
ES5 NXThcoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLkO4JI5O NIG4UGhUSU6JRWK=
HCC1599 NIDLSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Cbmp2UUN3ME2xNU46OSCwTR?= MXjTRW5ITVJ?
NCI-H23 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjM[lVKSzVyPUGyMlEzKG6P M2TmRnNCVkeHUh?=
NCI-H1581 NHjKfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHFRWJKSzVyPUGyMlI5KG6P MYPTRW5ITVJ?
JVM-3 M{PyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm5N5BKSzVyPUGyMlk6KG6P M4H2RnNCVkeHUh?=
NCI-SNU-1 M3vzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjWc41JUUN3ME2xN{4yQSCwTR?= M{PrUHNCVkeHUh?=
NB7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF3LkmyJI5O MYnTRW5ITVJ?
JAR M2XOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF4LkGzJI5O MmHBV2FPT0WU
TGW NYr0cnk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PlN2lEPTB;MU[uOFghdk1? NEfGRoFUSU6JRWK=
U-87-MG MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXESodKSzVyPUG2Mlc3KG6P NWS3O4hQW0GQR1XS
NCI-H1436 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LQXmlEPTB;MUeuNFEhdk1? MUnTRW5ITVJ?
GOTO M1vuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;vTWM2OD1zNz6wOkBvVQ>? MX3TRW5ITVJ?
COLO-800 NVHve3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O5S2lEPTB;MUeuOlQhdk1? NXHpcog6W0GQR1XS
MFM-223 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF5LkmxJI5O MkPrV2FPT0WU
EW-18 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnTWM2OD1zNz65OkBvVQ>? NUmwRVl1W0GQR1XS
NB14 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF5Lkm4JI5O MmLKV2FPT0WU
EB2 M1q3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF6LkC4JI5O M3nFZnNCVkeHUh?=
EoL-1- M3G2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jiXGlEPTB;MUiuN|Ehdk1? MVjTRW5ITVJ?
NCCIT MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXDTWM2OD1zOD6zOkBvVQ>? MXfTRW5ITVJ?
DG-75 NUjXdnRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jBXWlEPTB;MUiuOlEhdk1? M2fyWHNCVkeHUh?=
HCC2218 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\pNmlEPTB;MUmuOUBvVQ>? NH3KSJhUSU6JRWK=
TE-6 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1foXWlEPTB;MkCuNFghdk1? NGn5[JVUSU6JRWK=
SF539 M{e2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD1{MD62O{BvVQ>? MXfTRW5ITVJ?
NCI-H446 NWTE[JdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofYTWM2OD1{MT6xPEBvVQ>? MUXTRW5ITVJ?
IST-MES1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMfJY6UUN3ME2yNk44PyCwTR?= NH60Ro5USU6JRWK=
NCI-H82 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfKeWpsUUN3ME2yN{4xOiCwTR?= NGfGWFBUSU6JRWK=
HCC2157 NFnjR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD1{Mz6xN{BvVQ>? NH\3RWVUSU6JRWK=
EW-12 M3zsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS5TWM2OD1{Mz6xO{BvVQ>? NEnYWZZUSU6JRWK=
SIMA M3W3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfqR25sUUN3ME2yN{4{QCCwTR?= NX2zPYpkW0GQR1XS
DOHH-2 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK2NGZKSzVyPUKzMlQ2KG6P NFTGdlFUSU6JRWK=
IM-9 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL2TWM2OD1{Mz61OEBvVQ>? NYTwOZpjW0GQR1XS
EC-GI-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ2LkKzJI5O NIH1bYJUSU6JRWK=
HDLM-2 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ2LkW0JI5O MVzTRW5ITVJ?
LS-1034 M1z3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QXmlEPTB;MkWuO|Uhdk1? NFnLdoFUSU6JRWK=
REH MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e2dmlEPTB;Mk[uOFEhdk1? M4XwZnNCVkeHUh?=
LU-165 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132UWlEPTB;Mk[uO|Ihdk1? NGLueIlUSU6JRWK=
NH-12 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ixS2lEPTB;MkeuOlchdk1? M1y3Z3NCVkeHUh?=
WSU-NHL NWqwW|hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXYUXF4UUN3ME2yPE4{QSCwTR?= MlS3V2FPT0WU
ECC4 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ6Lke5JI5O MlfCV2FPT0WU
OCI-AML2 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2c2JKSzVyPUK5MlY6KG6P MXvTRW5ITVJ?
EW-3 NFOxbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC3TWM2OD1|MD61PUBvVQ>? NUX3UVVlW0GQR1XS
NCI-H526 NUn2WGVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqzXohCUUN3ME2zNk42PCCwTR?= MXjTRW5ITVJ?
NCI-H719 M13Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:wTWM2OD1|ND6zNUBvVQ>? MlTkV2FPT0WU
KARPAS-422 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnCTWM2OD1|NT6wOEBvVQ>? Ml\qV2FPT0WU
SK-MEL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2zeJhPUUN3ME2zOU4yPyCwTR?= MWXTRW5ITVJ?
ES3 NXfZ[3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OyRWlEPTB;M{WuNVkhdk1? NYjR[YhqW0GQR1XS
UACC-812 NYHUenduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX3TWM2OD1|NT60OEBvVQ>? MnnKV2FPT0WU
C8166 M3XGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXiTWM2OD1|NT63JI5O NGH4fIZUSU6JRWK=
MDA-MB-134-VI M{DKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\vTWM2OD1|NT64O{BvVQ>? M4DRW3NCVkeHUh?=
D-283MED MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLYbXdmUUN3ME2zO{44QSCwTR?= Mm\3V2FPT0WU
SHP-77 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP4T5pJUUN3ME2zPE4xOyCwTR?= NE[3OZhUSU6JRWK=
NCI-H2227 NE[xbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLCTWM2OD12MD60PUBvVQ>? NWryW5dMW0GQR1XS
SKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\DTWM2OD12Mj62N{BvVQ>? MWDTRW5ITVJ?
L-428 M2njbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTR|Lki2JI5O MkjOV2FPT0WU
RPMI-6666 NF25bY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf4R|RWUUN3ME20OU45QSCwTR?= MXzTRW5ITVJ?
NCI-H716 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR6LkixJI5O M{G4XXNCVkeHUh?=
DMS-79 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fXfWlEPTB;NUCuO|Ehdk1? NVGxdIsyW0GQR1XS
RS4-11 NHiyZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr5[HhKSzVyPUWwMlg5KG6P M2jV[XNCVkeHUh?=
NCI-H720 NEP4WnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HkemlEPTB;NUGuNVEhdk1? Mo\DV2FPT0WU
MC-CAR NIHu[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS3UXU4UUN3ME21NU42OiCwTR?= NH\yOpJUSU6JRWK=
TALL-1 NFHVe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlniTWM2OD13Mz65NUBvVQ>? MnmxV2FPT0WU
NCI-N87 NVuwVYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLRTWM2OD13ND6xPEBvVQ>? MUXTRW5ITVJ?
P30-OHK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0NmRKSzVyPUW0MlYyKG6P NETJfpdUSU6JRWK=
LP-1 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV64TXBUUUN3ME22NU4zQCCwTR?= M4e1OHNCVkeHUh?=
YT NUTveW5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;vbmFKSzVyPU[xMlghdk1? NVTN[IV{W0GQR1XS
MRK-nu-1 M3XiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHXTWM2OD14MT64NkBvVQ>? MXvTRW5ITVJ?
BT-474 NVTXWY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP5TWM2OD14NTDuUS=> NH;aV|ZUSU6JRWK=
NCI-H322M Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW2W413UUN3ME22Ok4yOSCwTR?= MWfTRW5ITVJ?
NCI-H128 NVTyNmV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPzO3FKSzVyPUe0Mlc4KG6P MV;TRW5ITVJ?
KMS-12-PE NVHzNYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnZTWM2OD15Nj6yOEBvVQ>? MWrTRW5ITVJ?
KP-N-YS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\YTWM2OD15Nj63OEBvVQ>? MlH1V2FPT0WU
ALL-PO M3HuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTsTWM2OD15Nz62OkBvVQ>? NEjmeWRUSU6JRWK=
EW-13 NGLReIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T1eGlEPTB;N{euO|Yhdk1? MmH0V2FPT0WU
EW-11 M1LQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr5coU2UUN3ME23PE42OiCwTR?= MknIV2FPT0WU
SK-N-FI NYnUXHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jjfmlEPTB;OECuNkBvVQ>? NU\WcXRHW0GQR1XS
CAL-148 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TCN2lEPTB;OEGuPFQhdk1? NHixU3hUSU6JRWK=
RL NF\yWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTh4LkC5JI5O M3XWeXNCVkeHUh?=
AM-38 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H1N2lEPTB;OEiuNFghdk1? NFrN[3BUSU6JRWK=
RH-1 NFr0VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTl7Lki1JI5O MX7TRW5ITVJ?
NCI-H1770 NFXF[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFyMj60PUBvVQ>? MVvTRW5ITVJ?
SIG-M5 NIH0bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ri[mlEPTB;MUC1MlA3KG6P MknjV2FPT0WU
GR-ST NGnXcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\4TWM2OD1zMUOuN|Qhdk1? Mn7YV2FPT0WU
ST486 NUPzT5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvrdnJKSzVyPUGxOE4xPiCwTR?= MUnTRW5ITVJ?
NCI-H1650 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFzNT6yPUBvVQ>? M1XwUnNCVkeHUh?=
MHH-CALL-2 NWPZTolMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L5[2lEPTB;MUG1Mlchdk1? NUnJ[XRuW0GQR1XS
BV-173 NXLxTmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3ZTWM2OD1zMkKuO|Ehdk1? MUPTRW5ITVJ?
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfCTWM2OD1zNEiuPFUhdk1? MV\TRW5ITVJ?
NCI-H524 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF3OT6xJI5O M3jrW3NCVkeHUh?=
SCLC-21H MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HDdWlEPTB;MUW5MlQyKG6P NITqR5BUSU6JRWK=
NCI-H1304 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\MR3dKSzVyPUG2PU4zOSCwTR?= NYm3XpdiW0GQR1XS
NCI-H510A NVq5SVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF6NT6zO{BvVQ>? M2XTeHNCVkeHUh?=
NCI-H209 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi2[4ViUUN3ME2xPVYvPTJibl2= NVv4[mxPW0GQR1XS
KM-H2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF7Nz6wOUBvVQ>? MnjHV2FPT0WU
NCI-H1395 M4\vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHSTWM2OD1{MUCuNVMhdk1? MVnTRW5ITVJ?
NCI-H1155 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ|MD6zNkBvVQ>? NFzIWFlUSU6JRWK=
COR-L279 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrwZ4ZKSzVyPUK1Nk4yPyCwTR?= NHvGOo5USU6JRWK=
NCI-H1299 NEXlSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ4MT63NUBvVQ>? MVPTRW5ITVJ?
EW-22 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLnTWM2OD1{NkOuO|Uhdk1? NE[5VlVUSU6JRWK=
SK-MEL-2 NF\ycppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe2VllKSzVyPUK4NU46KG6P Ml;kV2FPT0WU
KASUMI-1 M3HDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvNXoZKSzVyPUK4N{4xPSCwTR?= MVTTRW5ITVJ?
NCI-H187 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXVTWM2OD1{OEeuNFghdk1? M1m0R3NCVkeHUh?=
NCI-H2171 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XXWGlEPTB;Mki4MlkzKG6P MXrTRW5ITVJ?
LNCaP-Clone-FGC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XuUWlEPTB;Mkm1MlI3KG6P M2CxOHNCVkeHUh?=
NCI-H1522 NUjpWWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33hO2lEPTB;M{C3MlA2KG6P NHXSZVdUSU6JRWK=
SCH NXu3No14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP3VlFKSzVyPUOyNk4zOiCwTR?= M{W2VnNCVkeHUh?=
THP-1 NWO3NoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zHOmlEPTB;M{KyMlYhdk1? MnS3V2FPT0WU
SNU-C1 NYfJO2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzhR3BmUUN3ME2zOlIvODlibl2= M2f2O3NCVkeHUh?=
CA46 NIjOflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPnXnlKSzVyPUO3N{43OyCwTR?= NWSwdWZrW0GQR1XS
NCI-H1963 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvCc3VsUUN3ME2zPFYvOTlibl2= NVqyfo1VW0GQR1XS
DEL M4PST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPFV3piUUN3ME2zPVEvOjdibl2= M2C4NXNCVkeHUh?=
TUR MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPUTWM2OD1|OU[uOlEhdk1? NVu0VYhMW0GQR1XS
NCI-H226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRyMz6yN{BvVQ>? NGOyRYVUSU6JRWK=
COLO-668 M3LoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfBUGtKSzVyPUSwN{42PyCwTR?= NH\YOYlUSU6JRWK=
CPC-N MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XvfGlEPTB;NECzMlc4KG6P NEjibodUSU6JRWK=
NCI-H889 M4HCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO3c2kxUUN3ME20OlEvQTJibl2= Mn7NV2FPT0WU
J-RT3-T3-5 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zyRWlEPTB;NUOyMlU4KG6P NEGyTG9USU6JRWK=
MSTO-211H M{\GcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PiSGlEPTB;NUe0MlI3KG6P MnjTV2FPT0WU
SCC-15 M1\XO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv1R3Q4UUN3ME22OlcvPDdibl2= M37pU3NCVkeHUh?=
SUP-T1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHNVZhmUUN3ME22PFYvODRibl2= NEH3c25USU6JRWK=
DMS-153 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjkbWNKSzVyPUe0Ok45OyCwTR?= M1vFc3NCVkeHUh?=
MS-1 NU[2eo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1Nmc5UUN3ME23OVkvPDJibl2= MUjTRW5ITVJ?
TC-YIK M3TjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTd6MT6wNUBvVQ>? MYXTRW5ITVJ?
RPMI-8866 M1zPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiwb|RKSzVyPUGwNFYvOjhizszN NWeyNIhyW0GQR1XS
KY821 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljtTWM2OD1zMEO2MlA1KM7:TR?= MoTCV2FPT0WU
P31-FUJ NFXkbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITtfZhKSzVyPUGxNVIvPzVizszN MVrTRW5ITVJ?
COLO-824 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPrTWM2OD1zMk[xMlc5KM7:TR?= NWK1WGptW0GQR1XS
U-698-M NVjnN25GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkezTWM2OD1{Mk[yMlE2KM7:TR?= NGC0dZZUSU6JRWK=
TE-441-T NY\wS3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXITWM2OD1{NUKxMlch|ryP M{HmUXNCVkeHUh?=
IMR-5 M4XYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmyOoJRUUN3ME2zOFA6NjZ{IN88US=> NGnnV5dUSU6JRWK=
NCI-H1838 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO3TWM2OD12MUi2MlMzKM7:TR?= NIf6TZZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID